Without a doubt, anti-VEGF injections have transformed retinal treatments and the whole field of retina care. Here’s how they work and why they’ve given millions of patients a real chance at keeping their vision.
A generation ago, conditions like wet macular degeneration, diabetic macular edema, and retinal vein occlusion were largely untreatable. Patients were told to expect vision loss and given little else. In short, they just went blind within about a year. The arrival of anti-VEGF therapy changed that completely. Today, these medications are the standard of care for some of the most common causes of blindness in adults — and they work in a way that targets the root biological cause of vision-threatening retinal disease.
What Is VEGF and Why Does It Cause Problems?
VEGF stands for vascular endothelial growth factor. It’s a protein your body produces naturally to stimulate the growth of new blood vessels — a process called angiogenesis. In healthy tissue, VEGF plays a useful role: it helps wounds heal, supports normal fetal development, and maintains vascular health.
In the retina, however, excess VEGF becomes destructive. Several common retinal diseases cause the eye to overproduce VEGF — either in response to oxygen deprivation (as in diabetic retinopathy), abnormal tissue signaling (as in wet macular degeneration), or blocked blood flow (as in retinal vein occlusion). When VEGF levels spike, abnormal new blood vessels grow rapidly under or within the retina. These vessels are structurally fragile and prone to leaking. Fluid seeps into the macula — the central zone of the retina responsible for sharp, detailed vision — causing swelling, distortion, and, if untreated, permanent damage to the photoreceptors that power your central sight.
How Do Anti-VEGF Drugs Stop This?
Anti-VEGF drugs work by intercepting VEGF molecules before they can bind to their receptors on blood vessel cells. Without that binding signal, the vessels can’t grow and can’t leak. The result: fluid stops accumulating, existing abnormal vessels stabilize or regress, and the macula has a chance to recover.
The drugs are administered directly into the vitreous — the gel-like fluid that fills the inside of the eye — so they reach the retina in high concentrations without needing to travel through the bloodstream. Different anti-VEGF agents work in slightly different ways:
- Avastin (bevacizumab) and Lucentis (ranibizumab) — second-generation agents that bind and neutralize VEGF-A. Often the starting point under insurance requirements.
- Eylea (aflibercept) and its biosimilar PavBlu — third-generation agents that act as decoy receptors, trapping both VEGF-A and placental growth factor (PlGF) with high affinity. Broader mechanism, longer duration.
- Eylea HD (aflibercept 8 mg) — a higher-dose version of aflibercept, delivering four times the molar dose of standard Eylea for potentially longer intervals between injections. Fourth generation
- Vabysmo (faricimab) — a fourth-generation agent that blocks both VEGF-A and angiopoietin-2 (Ang-2), a separate pathway that destabilizes blood vessels. Dual blockade gives it a distinct mechanism from all prior agents.
All of these drugs share the same core goal: stop VEGF from triggering abnormal vessel growth and leakage in the retina. The differences lie in their molecular targets, their potency, and how long each injection’s effect lasts.
Which Conditions Respond to Anti-VEGF Treatment?
Anti-VEGF therapy is the primary treatment for several major retinal diseases:
- Wet (neovascular) age-related macular degeneration (AMD) — the most common indication. Anti-VEGF injections stop the growth of the abnormal blood vessels beneath the macula that define wet AMD and are the leading cause of severe vision loss in adults over 50 in Oregon and nationwide.
- Diabetic macular edema (DME) — fluid accumulation in the macula caused by diabetic damage to retinal blood vessels. Anti-VEGF dramatically reduces this swelling and is now the first-line treatment for DME.
- Diabetic retinopathy (DR) — anti-VEGF has also been shown to reduce the severity of diabetic retinopathy itself, not just its macular complications.
- Retinal vein occlusion (RVO) — when a vein in the retina becomes blocked, VEGF surges in the oxygen-starved tissue downstream. Anti-VEGF controls the resulting macular edema and abnormal vessel growth.
- Cystoid Macular Edema (CME) – retinal swelling from multiple other causes. Anti-VEGF medications work well for many of these conditions, although are off lable.
- Central Serous Retinopathy (CSR) – while off label, anti-VEGF injections can often help reduce the sub-retinal fluid accumulation in this condition.
What Results Can Patients Expect?
Results vary by condition and by how early treatment begins — but the data across all major anti-VEGF trials are consistent and striking. In wet AMD clinical trials, more than 90% of patients treated with anti-VEGF maintained their baseline vision, and roughly one-third gained significant vision. In DME trials, many patients saw meaningful improvements in visual acuity after consistent treatment.
The earlier treatment starts, the better the outcome. Retinal cells damaged by chronic fluid accumulation or prolonged abnormal vessel growth may not fully recover. Anti-VEGF can stop the damage from progressing and, in many cases, reverse it — but it cannot restore cells that have already been lost. For patients across Oregon’s Willamette Valley and coast who notice sudden changes in their central vision, prompt evaluation is essential.
What Was Retinal Care Like Before Anti-VEGF?
Before anti-VEGF therapy arrived in the mid-2000s, the options for wet AMD were limited to laser photocoagulation — burning leaking vessels with a laser — and a treatment called photodynamic therapy. Both slowed the disease but rarely improved vision. Many patients still lost significant central sight over time.
The FDA approval of Lucentis for wet AMD in 2006 marked a genuine turning point. For the first time, a treatment could not only stop vision loss but reverse it in a meaningful percentage of patients. Retinal specialists who practiced through that era describe it as one of the most significant shifts in the history of eye care. The anti-VEGF era has since expanded far beyond wet AMD, fundamentally changing outcomes for millions of people with diabetic eye disease and retinal vein occlusion as well.
Are Anti-VEGF Injections a Cure?
No — and this is an important distinction for patients to understand. Anti-VEGF drugs control the disease; they don’t eliminate it. The conditions driving excess VEGF production — wet AMD, diabetic retinopathy, retinal vein occlusion — are chronic. When the medication wears off, VEGF levels can rise again, fluid can return, and disease activity can resume.
This is why ongoing treatment is necessary for most patients. The goal is to maintain the eye in a stable, fluid-free state with the fewest injections needed. Most retina specialists use a “treat and extend” approach: injections continue at whatever interval keeps the disease controlled, extending the gap between visits when the eye looks stable and tightening it when activity returns. For many patients, this eventually means injections every 8 to 12 weeks. Reaching 16-week intervals is possible for some — but that’s the uncommon exception, not what most patients should expect as a baseline.
How Long Do Patients Need Anti-VEGF Treatment?
For some conditions treated with anti-VEGF, treatment is long-term — often indefinite, especially for Wet and Dry AMD. Wet AMD, once present, doesn’t resolve on its own. Diabetic retinopathy reflects systemic disease that persists as long as the underlying diabetes is active and progressing. Retinal vein occlusion can sometimes stabilize over time, and some patients eventually discontinue treatment, but others require ongoing injections for years.
Studies of patients with wet AMD who discontinued anti-VEGF after several years of successful treatment have generally found that most eventually experience disease reactivation. The consistent finding across the literature is that sustained treatment produces better long-term outcomes than stopping early. For patients in Roseburg, Salem, Eugene, and communities along the Oregon coast who are managing chronic retinal disease, a reliable treatment relationship with a retina specialist matters as much as the medication itself.
The Bottom Line
Anti-VEGF therapy is one of the genuine success stories of modern medicine. It works by cutting off the molecular signal that drives abnormal blood vessel growth and leakage in the retina — a mechanism that, once understood, made effective treatment of wet AMD, diabetic macular edema, and retinal vein occlusion possible for the first time. The drugs have improved, the dosing intervals have lengthened, and the outcomes keep getting better. For patients facing these diagnoses today, the prognosis is far more favorable than it was even 15 years ago.
Dr. Peter Karth leverages best anti-VEGF medications to give patients the best possible outcomes.
At Retina Care, retinal specialist Peter Karth, MD, MBA, FASRS, FACS is happy to help you with your retina concerns. Please call 541-8-RETINA or 541-873-8462 to schedule an appointment at a location near you.